Gilead, Merus Strike Deal to Develop Novel Trispecific T-Cell Antibodies for Cancer Treatment
Agreement to focus on research, option, and licensing for discovery of dual tumor-associated antigen-targeting antibodies.
August 17, 2026
Breaking News
Can an Office harassment lawyer negotiate a settlement? |
Why is Jack Bodenstein gaining attention? |
Which 100 Series Dash Mats offer the best fit and protection? |
Is oven repair Ottawa worth it for older electric and gas ovens? |
How often should organizations conduct a cloud penetration test? |
